Replies to post #2814 on Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

Recent setbacks in T-cell therapy, such as Atara Biosecience's failure in MS, raise questions about the field's overall effectiveness. This could potentially remove a competitor from the RSV space, making ALVR106 more attractive to larger pharmaceutical companies.

I know nothing about ALVR except from your recent posts. However, it appears that they are using the same kind of T-cell therapy so why would Atara's failure benefit ALVR?